50 results about "CD90" patented technology

The invention discloses an antibody combination and a system for detecting leukemia stem cells. The antibody combination comprises a CD7 antibody, a CD371 antibody, a CD34 antibody, a CD45RA antibody, a CD123 antibody, a CD133 antibody, a CD38 antibody, a CD45 antibody, a CD90 antibody, a CD33 antibody and a CD19 antibody. The antibody combination provided by the invention can accurately identify target cells and distinguish normal HSCs and pluripotent progenitor cells in a CD34 + CD38-cell population, and the specific antibody has abnormal expression or expression intensity change, so that leukemia stem cells can be rapidly, simply and conveniently detected with high accuracy, high sensitivity and high specificity, the sensitivity of MRD evaluation is favorably improved, and the kit has a good application prospect. Therefore, signs of disease recurrence can be found earlier, more information about disease prognosis can be provided, and doctors and patients can be helped to better understand disease prognosis and possible results.

The present invention provides a method of producing a population of mesenchymal stromal cells (MSC) of CD73 + CD44 +, CD90 +. The CD73 + CD44 +, CD90 + MSC is used in a method for producing terminally differentiated osteoblasts, adipoblasts and chondroblasts from pluripotent stem cells (PSCs). The differentiation methods include the use of a single agent-a WNT signaling pathway activator used on an adherent culture of PSC, such as a GSK3 [beta] inhibitor.

The present invention relates to CD73 + CD44 + , CD90 + A method for generating a population of mesenchymal stromal cells (MSCs) is provided. + CD44 + , CD90 + MSCs are used in methods to generate terminally differentiated osteogenic, adipogenic, and chondrogenic cells from pluripotent stem cells (PSCs), which involve the use of a single agent, a WNT signaling pathway activator (e.g., a GSK3β inhibitor), in adherent cultures of PSCs.

The present invention discloses an in vitro preparation method of human mesenchymal stem cells. The method comprises the following steps: using MSC culture medium supplemented with chemical small molecules to induce iPSC-derived MSCs; after the iPSC cell confluence reaches 40%, the culture medium containing chemical small molecules is replaced; after 8-10 days of induction, the cells are collected and passaged; and the cells are cultured to the P1 generation, showing uniform fibroblast-like, spindle-shaped or fusiform cells. The prepared hiPSC-MSCs meet the relevant phenotypes of mesenchymal stem cells, wherein the positive rates of CD73, CD90 and CD105 are higher than 95%, and the cells have immunomodulatory activity.

The present invention provides a combination comprising a) an antigen binding domain specific for CD90, and b) an antigen binding domain specific for CD326, for use in treatment of human cancer comprising cancerous cells that co-express CD90 and CD326. In one embodiment of the invention the combination comprises a) an immune cell comprising a CAR comprising an antigen binding domain specific for a tag of a first and a second polypeptide, b) said tagged first polypeptide that has an antigen binding domain specific for CD90, and c) said tagged second polypeptide that has an antigen binding domain specific for CD326, wherein the tag of the first polypeptide and the tag of the second polypeptide are identical. In a further embodiment the concentrations used for said first and that second polypeptide are below the activation threshold of said CAR, respectively, but the sum of both concentrations is above the activation threshold of said CAR.

The present invention relates to the technical field of biology, and particularly relates to a method for inhibiting an inflammatory response by using a fibroblast. In the present invention, a fibroblast, which is obtained by digesting normal foreskin tissue by means of clostridiopeptidase A to isolate a cell as a seed cell and culturing the seed cell in vitro by using a serum-free medium, shows positive expression of CD105, CD90, CD73, COL1A1, and FAP, with expression rates all exceeding 80%, and negative expression of CD36, CD39, CD45, and HLA class II molecules, with expression rates below 5%. The fibroblast can regulate an immune response by secreting TGFβ, inhibiting proliferation of PBMCs, thereby inhibiting the inflammatory response, and has been verified in an animal experiment to have the ability to repair knee osteoarthritis caused by meniscus injury. Therefore, the fibroblast can be used for preventing and treating inflammatory lesions such as osteoarthritis.

This invention provides a cell population comprising mesenchymal cells capable of forming a cell sheet that can be spontaneously detached from a substrate. In such cell population comprising mesenchymal cells, the proportion of cells positive for CD324 is 70% or more and the proportion of mesenchymal cells positive for CD90 is 90% or more.

To provide safe and high-performance stem cells appropriate for clinical application, and a method for producing the stem cells.SOLUTION: Provided are a stem cell population derived from human deciduous tooth dental pulp, wherein 90% or more of the stem cell population is characterized by being CD117-negative, CD73-positive, CD90-positive, and CD105-positive, and a method for producing a stem cell population derived from human deciduous tooth dental pulp, the method comprising a step of culturing cells isolated from human deciduous tooth dental pulp in a medium that does not contain FBS (fetal bovine serum) in the presence of human platelet lysate (hPL).SELECTED DRAWING: None

A method for treating subjects with graft-versus-host disease (GvHD) or at risk of developing GvHD, using CD90 with stronger immunomodulatory capabilities. + hAEC cell populations were used as the primary therapeutic cells. Studies on the related mechanism of action revealed that CD90... + hAECs showed significantly higher levels of stem cell pluripotency markers SSEA4, OCT4, and NANOG than typical hAECs, and also exhibited better immunomodulatory functions; therefore, CD90 was used as a marker. + hAECs cells can be used as a treatment to achieve better clinical outcomes.

This invention relates to the field of cell detection technology, specifically to a reagent tube for detecting mesenchymal stem cell phenotypes. The tube includes a reagent tube body and pre-encapsulated fluorescent antibody lyophilized microspheres. The lyophilized microspheres are formed by lyophilization of a mixture of lyophilization protection solution and fluorescently labeled antibody. The fluorescently labeled antibody is a combination of antibodies targeting positive markers of mesenchymal stem cell phenotypes CD73, CD90, and CD105, or a combination of antibodies targeting negative markers CD45, CD34, CD11b, CD19, and HLA-DR. This invention offers high efficiency and convenience: by pre-encapsulating the fluorescent antibody lyophilized microspheres, the traditional three-step process of "antibody preparation-sample addition-mixing" is simplified to direct addition of cell suspension. The single-sample detection time is reduced from 120 minutes to 30 minutes, the number of pipetting operations is reduced by 80%, and human error is significantly reduced.

Disclosed are a specific marker combination of mesenchymal stem cell-derived small extracellular vesicles and the use thereof. The characteristic marker combination comprises aminopeptidase N (CD13), integrin β-1 (CD29), membrane glycoprotein THY-1 (CD90), and markers CD9, CD63 and CD81. By using the characteristic marker combination of mesenchymal stem cell-derived small extracellular vesicles for nano-flow cytometry analysis at the single-vesicle level, mesenchymal stem cell-derived small extracellular vesicles can be identified. On the basis of the provided characteristic marker combination, specific modification and engineering on the basis of small extracellular vesicle membrane proteins can further be realized.

The invention relates to a stem cell technology, in particular to a pet stem cell induction culture medium, a preparation method and a culture method, and the culture medium significantly improves the proliferation efficiency and multidirectional differentiation potential of adipose-derived stem cells by optimizing the proportion of specific growth factors. The preparation method comprises the steps of basic culture medium preparation, growth factor addition and sterile filtration. Experimental verification shows that compared with a control group, the adipogenic differentiation efficiency of ADSCs cultured by the culture medium is improved by 40%, the osteogenic differentiation ALP activity is improved by 65%, and the positive rates of surface markers CD29, CD44 and CD90 are all greater than or equal to 95%. The problems of animal-derived pathogen pollution risk and low induction efficiency of a traditional culture medium are solved, and the culture medium is suitable for pet medical treatment.

The invention provides an application of a composition, a culture medium additive or a culture medium in amplifying hematopoietic stem cells or preparing products for amplifying the hematopoietic stem cells. On the first aspect, the invention provides application of the composition, the culture medium additive or the culture medium to hematopoietic stem cell amplification or hematopoietic stem cell amplification product preparation. The composition comprises quininostat and resveratrol. The culture medium additive comprises a composition; the culture medium comprises a basic culture medium and an additive, wherein the additive comprises the composition. By screening the combination of a specific HDAC inhibitor and other various different small molecule compounds, the proportion of CD34 +, CD34 + CD90 + and CD34 + CD90 + EPCR + cells of HSC after in-vitro amplification can be obviously improved at a lower working concentration, namely, the proportion of hematopoietic stem cells and long-acting hematopoietic stem cells can be improved.

This application provides the use of a composition, culture medium additive, or culture medium in expanding hematopoietic stem cells or preparing products containing expanded hematopoietic stem cells. A first aspect of this application discloses the use of a composition, culture medium additive, or culture medium in expanding hematopoietic stem cells or preparing products containing expanded hematopoietic stem cells. The composition includes quinsinostat and resveratrol; the culture medium additive includes the composition; the culture medium includes a basal medium and an additive, the additive including the composition. By screening specific HDAC inhibitors and combinations of various other small molecule compounds, the CD34 concentration of HSCs after in vitro expansion can be significantly increased at lower working concentrations. + CD34 + CD90 + and CD34 + CD90 + EPCR + The proportion of cells, that is, the proportion of hematopoietic stem cells and long-acting hematopoietic stem cells, can be increased.

Provided are methods and compositions conditioning a patient for an allogeneic transplantation, wherein the patient's hematopoietic stem cells (HSCs) are depleted with an HSC-depleting composition and the patient is then administered allogeneic cells selected from bone marrow cells, umbilical cord blood cells, hematopoietic stem and progenitor cells (HSPCs), peripheral blood CD34+ cells, and peripheral blood CD34+ and CD90+ cells; optionally the patient is also administered a medicament selected from the group consisting of a T-cell depleting or inhibiting antibody or antibody fragment, NK-cell depleting or inhibiting antibody or antibody fragment, immunosuppressive drug, and any combination thereof. The HSC-depleting composition comprises a compound selected from the group consisting of: an antibody or antibody fragment with specific binding affinity to a protein displayed at the HSC surface, a conjugate comprising an HSC-recognition molecule and a toxin, and any combination thereof.

The invention belongs to the field of biological medicine, and particularly discloses a culture method of domesticated mesenchymal stem cells (MSCs), which comprises the following steps: separating plasma and platelet lysis buffer from autologous peripheral blood, and obtaining CTL and Treg through magnetic bead sorting; the method comprises the following steps: sequentially co-culturing umbilical cord MSCs for three generations: co-culturing the P1 generation and CTL in a culture medium containing 30% of alpha MEM, 68% of DMEM / F12, 1% of autologous plasma and 1% of platelet lysis buffer, and adding 0.1-1 [mu] M of resveratrol and 10-50 [mu] M of spermidine; co-culturing P2 and Treg in a culture medium containing 50% of alpha MEM, 48% of DMEM / F12, 1% of autologous plasma and 1% of platelet lysis buffer; the P3 generation is cultured and harvested in 90% of alpha MEM, 5% of DMEM / F12 and 5% of PRP. The obtained MSCs surface marker is CD105 < + > / CD90 < + > / CD73 < + > / CD45 <-> / CD34 <-> / HLA-DR <->, the expression quantity of CD24 is low (CD24low), the expression quantity of CD47 is high (CD47high), the expression quantity of PD-L1 is high (PD-L1 high), the IDO activity is larger than or equal to 25 U / mg, the retention rate of the lung after vein transplantation is smaller than or equal to 12%, and the survival period is larger than or equal to 28 days. The cell is suitable for treating ARDS or hepatic fibrosis.

The present disclosure relates to a method for producing mesenchymal stem cells for therapeutic applications. The method comprises culturing of MSCs to obtain heterogeneous population. This heterogeneous population of MSCs were subjected to droplet encapsulation media to obtain a population of microfluidic droplets preferably comprising a single MSC; providing the population of microfluidic droplets to a microfluidics device; and identifying and selecting a homogeneous population of MSCs having medium size in the range of 15 to 30 μm showing high expression of cell surface markers (CD73, CD90) and increased expression of genes, such as COL12 A1; IGFBP5; THBS2; GREM1 and CDH2 genes. The MSCs having medium size are further cryopreserved to obtain a cell bank of MSCs with better stability and therapeutic potential in treating diseases like auto immune diseases.

Provided are methods and compositions conditioning a patient for an allogeneic transplantation, wherein the patient's hematopoietic stem cells (HSCs) are depleted with an HSC-depleting composition and the patient is then administered allogeneic cells selected from bone marrow cells, umbilical cord blood cells, hematopoietic stem and progenitor cells (HSPCs), peripheral blood CD34+cells, and peripheral blood CD34+ and CD90+ cells; optionally the patient is also administered a medicament selected from the group consisting of a T-cell depleting or inhibiting antibody or antibody fragment, NK-cell depleting or inhibiting antibody or antibody fragment, immunosuppressive drug, and any combination thereof. The HSC-depleting composition comprises a compound selected from the group consisting of: an antibody or antibody fragment with specific binding affinity to a protein displayed at the HSC surface, a conjugate comprising an HSC-recognition molecule and a toxin, and any combination thereof.

The application belongs to the field of cell culture. The application provides a culture medium of rat amniotic membrane mesenchymal stem cells and a culture method of rat amniotic membrane mesenchymal stem cells. The culture medium is a complete culture medium, and the culture method is as follows: the rat amnion is cut into tissue blocks smaller than 2mm 2 , is uniformly laid in a culture dish with a spacing of 0.3-0.8cm, complete culture medium is slowly added after the tissue blocks are adhered, the culture medium is supplemented after 12h-36h, the primary medium replacement is performed after 48h-72h of culture, the impurity cells are removed, and the cells are subcultured when the cell fusion degree reaches 80%-90%. The light microscope observation and identification result show that the rat amniotic membrane mesenchymal stem cells cultured by the application basically conform to the cell morphology of rat amniotic membrane mesenchymal stem cells, the CD90&DAPI immunofluorescence identification result shows that the cell purity is greater than or equal to 90%, the cells have the characteristics of stem cells, and the culture method is efficient in amplification.

Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.

The present invention relates to a method of inducing or improving wound healing properties of a mesenchymal stem cell population, the method comprising cultivating the mesenchymal stem cell population in a culture medium comprising DMEM (Dulbecco's modified eagle medium), F12 (Ham's F12 Medium), M171 (Medium 171) and FBS (Fetal Bovine Serum). The invention also relates to a mesenchymal stem population, wherein at least about 90% or more cells of the stem cell population express each of the following markers: CD73, CD90 and CD105 and lack expression of the following markers: CD34, CD45 and HLA-DR. The invention also relates to a pharmaceutical composition of this mesenchymal stem population.

The invention belongs to the technical field of biological medicines, and particularly relates to application of mesenchymal stem cells combined with mesalazine in preparation of an anti-IBD (infectious bursal disease) medicine. The mesenchymal stem cells are mesenchymal stem cells from human umbilical cord; the human umbilical cord mesenchymal stem cells highly express CD73, CD90 and CD65, and low express CD34, CD45 and HLA-DR (Human Leukocyte Antigen-DR). The research finds that the hUC-MSCs has a remarkable treatment effect on a chronic IBD mouse model when being singly used or combined with 5-ASA for treatment, the hUC-MSCs and drug combination can restore the intestinal microecological balance by adjusting the composition of intestinal flora so as to improve the symptoms of IBD, and the hUC-MSCs and the drug combination have a synergistic effect when being combined with 5-ASA for treatment. The invention provides a new thought and experimental basis for clinical treatment of IBD.

The present invention provides compositions and methods for promoting the engraftment of exogenous hematopoietic stem cell grafts and for maintaining the pluripotency and hematopoietic function of these cells after transplantation. [Solution] The present invention provides compositions and methods useful for the depletion of cells such as CD45+, CD135+, CD34+, CD90+, and / or CD110+ cells, and, in particular, for the treatment of various hematopoietic disorders, metabolic disorders, cancer, and autoimmune diseases. For example, antibodies, their antigen-binding fragments, ligands, and conjugates that can be applied to achieve the treatment of these conditions by depleting populations of D45+, CD135+, CD34+, CD90+, or CD110+ cells in a patient such as a human are described herein.

This invention relates to a ZIF-8-based composite nanoparticle with a core-shell structure. The core is a zeolite imidazole ester backbone ZIF-8 carrier, and the pores of the ZIF-8 core are loaded with a photothermal agent. Liposomes are coated on the outer surface of the core as a shell, and CD90 antibodies are coupled to the surface of the liposomes. The composite nanoparticle targets mesenchymal stem cells, thereby more effectively delivering zinc ions into mesenchymal stem cells (MSCs) to regulate MMP-10 (matrix metalloproteinase-10) expression. The composite nanoparticle can be used to prepare drugs or medical dressings for treating bone defects and / or promoting vascularized bone regeneration.

The present invention provides a method of producing a thymic construct suitable for implantation into a subject, the method comprising the steps of: (i) providing a decellularised scaffold; (ii) seeding the decellularised scaffold with thymic epithelial cells having mesenchymal properties; and (iii) culturing the seeded scaffold to produce the construct. The thymic epithelial cells are preferably CD49f + , also VIM + , TE-7 + , and / or CD90 + . The present invention further provides pharmaceutical compositions, uses and therapies using thymic epithelial cells having mesenchymal properties.

The present invention provides a human megakaryocyte-biased hematopoietic stem cell molecular marker and a detection kit thereof. The detection marker of the present invention fills the gap in the prior art for the identification of surface molecular markers of human megakaryocyte-biased hematopoietic stem cells, creatively discovers that megakaryocyte hematopoietic stem cells are enriched in CD34 + CD38 ‑ CD45RA ‑ CD90 + CD49f low Cell populations, using this marker to identify cell subpopulations or screen for the preparation of cell therapy preparations has broad application prospects and great improvements in scientific research and clinical practice.

The invention provides an endometrial stem cell preparation as well as a preparation method and application thereof, and belongs to the technical field of biological preparations. According to the preparation method of the endometrial stem cell preparation, the safety risk is controlled through an autoserum source, the cell function is optimized in combination with a low-oxygen environment, and a high-stability and low-immune-risk standardized solution is provided for clinical transformation of the endometrial stem cell preparation. Three batches of culture data show that the cell viability is gt; the mesenchymal stem cell culture medium is stable in form and meets the mesenchymal stem cell verification standard. The flow detection verification shows that the positive rate of CD73 / CD90 / CD105 is greater than or equal to 95%, the negative markers such as CD34 / CD45 and the like are less than or equal to 2%, and the high purity is proved; the cell cycle shows that the G0 / G1 period accounts for 74-80%, and the resting state and the genome stability are maintained. After the preparation provided by the invention is stored for a short time or frozen and unfrozen for a long time, the cell morphology and proliferation capacity are not obviously attenuated.

The invention provides methods for generating human CD34+, CD43+, and CD90+ hematopoietic progenitor cells from hematopoietic stem cells. The methods include the use of chemically-defined culture media. Isolated cell populations are also provided.

The invention provides methods for generating human CD34+, CD43+, and CD90+ hematopoietic progenitor cells from hematopoietic stem cells. The methods include the use of chemically-defined culture media. Isolated cell populations are also provided.